Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations

Allergan Reiterates Strong Standalone Growth Profile and Strategy Following Termination of Pfizer Transaction

DUBLIN, April 6, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced that its merger agreement with Pfizer (NYSE: PFE) has been terminated by mutual agreement, effective today. In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

Allergan reiterated its compelling standalone growth profile and strategy following the... More

Pfizer Announces Termination of Proposed Combination with Allergan

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an Adverse Tax Law Change under the merger agreement.

Pfizer approached this transaction from a position of strength and viewed the potential combination as an accelerator of existing strategies, stated Ian Read, Chairman and Chief Executive... More

Pfizer and Allergan Issue Statement

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) today issued the following statement regarding the recently issued Department of Treasury Notice:

We are conducting a review of the U.S. Department of Treasurys actions announced today. Prior to completing the review, we wont speculate on any potential impact.

NO OFFER OR SOLICITATION

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an... More